File(s) stored somewhere else
Please note: Linked content is NOT stored on La Trobe and we can't guarantee its availability, quality, security or accept any liability.
Cardiovascular and metabolic protection by vitamin E: A matter of treatment strategy?
journal contributionposted on 2021-01-14, 22:49 authored by M Ziegler, M Wallert, S Lorkowski, Karlheinz PeterKarlheinz Peter
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. Cardiovascular diseases (CVD) cause about 1/3 of global deaths. Therefore, new strategies for the prevention and treatment of cardiovascular events are highly sought-after. Vitamin E is known for significant antioxidative and anti-inflammatory properties, and has been studied in the prevention of CVD, supported by findings that vitamin E deficiency is associated with increased risk of cardiovascular events. However, randomized controlled trials in humans reveal conflicting and ultimately disappointing results regarding the reduction of cardiovascular events with vitamin E supplementation. As we discuss in detail, this outcome is strongly affected by study design, cohort selection, co-morbidities, genetic variations, age, and gender. For effective chronic primary and secondary prevention by vitamin E, oxidative and inflammatory status might not have been sufficiently antagonized. In contrast, acute administration of vitamin E may be more translatable into positive clinical outcomes. In patients with myocardial infarction (MI), which is associated with severe oxidative and inflammatory reactions, decreased plasma levels of vitamin E have been found. The offsetting of this acute vitamin E deficiency via short-term treatment in MI has shown promising results, and, thus, acute medication, rather than chronic supplementation, with vitamin E might revitalize vitamin E therapy and even provide positive clinical outcomes.
Deutsche Forschungsgemeinschaft: RTG 1715, Collaborative Research Centre (SFB): 1278, German Federal Ministry of Education and Research: 01EA1411A, Free State of Thuringia and the European Social Fund: 2019 FGR 0095, NHMRC: Investigator L3 fellowship.
Article NumberARTN 935
Rights StatementThe Author reserves all moral rights over the deposited text and must be credited if any re-use occurs. Documents deposited in OPAL are the Open Access versions of outputs published elsewhere. Changes resulting from the publishing process may therefore not be reflected in this document. The final published version may be obtained via the publisher’s DOI. Please note that additional copyright and access restrictions may apply to the published version.
Science & TechnologyLife Sciences & BiomedicineBiochemistry & Molecular BiologyChemistry, MedicinalFood Science & TechnologyPharmacology & Pharmacyvitamin Ecardiovascular diseasemyocardial infarctionrisk factorstreatment strategyALPHA-TOCOPHEROL SUPPLEMENTATIONTYPE-2 DIABETIC-PATIENTSLOW-DENSITY-LIPOPROTEINHAPTOGLOBIN 2-2 GENOTYPELONG-CHAIN METABOLITESC-REACTIVE PROTEINOXIDATIVE STRESSGAMMA-TOCOPHEROLBLOOD-PRESSUREMYOCARDIAL-INFARCTION